港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维升药业-B

33.400

+0.3801.15%

成交量：5.65万

成交额：188.59万

市值：38.08亿

市盈率：-17.16

高：33.800

开：33.040

低：32.800

收：33.020

52周最高：69.150

52周最低：32.800

股本：1.14亿

香港流通股本：1.14亿

量比：1.61

换手率：0.05%

股息：- -

股息率：- -

每股收益(LYR):-1.946

净资产收益率：-57.66%

总资产收益率：-29.52%

市净率：4.07

市盈率(LYR):-17.16

市销率: 4140.97

数据加载中...

总览公司新闻资讯公告

每日卖空追踪 | 维升药业-B 11月14日卖空量成交100股，卖空比例为0.22%

维升药业尾盘涨超4%公司在进博会达成多项合作携两款全球创新药物登场亮相

维升药业-B盘中异动早盘股价大跌5.02%

打破“进口依赖”，中国医药企业创新速度提升

中国新闻网

直通进博会 | 进博首秀即双签约！维升药业携手东富龙、临港新片区共筑生物医药生态

维升药业进博首秀：“全球创新、中国加速”战略持续落地

维升药业-B(02561.HK)涨超4%

每日经济新闻

港股异动 | 维升药业-B(02561)涨超4% 帕罗培特立帕肽近期在博鳌完成首例处方

维升药业-B(02561)：陆楹已获委任为首席财务官

维升药业-B10月13日主力净流出23.9万元散户资金买入

维升药业-B10月09日主力净流出51.8万元散户资金买入

维升药业-B午前涨超3% 隆培促生长素有望年内获批上市

创新药全链条高景气持续，维升药业-B(02561)或迎“戴维斯双击”

维升药业-B09月23日遭主力抛售21.5万元

大摩：市场对生物科技股认可度提升推动股价跑赢大市看好康方生物(09926)等

维升药业-B09月22日主力净流出57.1万元散户资金买入

维升药业-B09月16日主力净流入90.1万元散户资金抛售

横盘迷雾下的价值火山：维升药业-B（2561.HK）正站在价值重构临界点

长效生长激素“元年”启幕，从“日剂”到“周剂”百亿市场竞争格局生变

维升药业-B(02561)发布中期业绩研究及开发成本4662.1万元同比增加19.8%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02561/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维升药业-B","latestPrice":33.4,"timestamp":1763366895005,"preClose":33.02,"halted":0,"volume":56500,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"已收盘","change":0.38,"latestTime":"11-17 16:08:15","open":33.04,"high":33.8,"low":32.8,"amount":1885898,"amplitude":0.030285,"askPrice":34.8,"askSize":1600,"bidPrice":33.1,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-2.238552,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":33.02,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":1.60694,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":1.60694,"shares":113999999,"dividePrice":0,"high":33.8,"amplitude":0.030285,"preClose":33.02,"low":32.8,"week52Low":32.8,"pbRate":"4.07","psRate":"4140.97","week52High":69.15,"institutionHeld":0,"latestPrice":33.4,"committee":0.304348,"eps":-1.946273,"divideRate":0,"volume":56500,"delay":0,"ttmEps":-2.238552,"open":33.04,"prevYearClose":68.8,"prevWeekClose":33.02,"prevMonthClose":38.02,"prevQuarterClose":42.5,"fiveDayClose":35.08,"twentyDayClose":41.16,"sixtyDayClose":46.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1746288000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2025-11-14","current":-14.920359,"percent":1,"low":-30.760225,"twenty":-27.750423,"median":-26.249352,"eighty":-18.799844,"high":-14.606062,"avg":-24.435891,"sd":4.206592,"marketCap":3467805439},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412},{"date":"2025-07-25","current":-27.917728,"twenty":-28.10544,"median":-27.177054,"eighty":-25.808828,"marketCap":5582416336},{"date":"2025-08-01","current":-26.858726,"twenty":-28.252573,"median":-27.236899,"eighty":-25.835301,"marketCap":5337473578},{"date":"2025-08-08","current":-26.45431,"twenty":-28.168194,"median":-27.174901,"eighty":-25.937332,"marketCap":5270256728},{"date":"2025-08-15","current":-27.513449,"twenty":-28.142473,"median":-27.236899,"eighty":-26.012565,"marketCap":5473046546},{"date":"2025-08-22","current":-26.703746,"twenty":-28.118557,"median":-27.177054,"eighty":-26.021282,"marketCap":5295320638},{"date":"2025-08-29","current":-26.119434,"twenty":-28.10544,"median":-27.144467,"eighty":-26.021282,"marketCap":5204179147},{"date":"2025-09-05","current":-23.791598,"twenty":-28.093765,"median":-27.114576,"eighty":-25.835301,"marketCap":4735670561},{"date":"2025-09-12","current":-23.381705,"twenty":-28.083375,"median":-27.05699,"eighty":-25.694259,"marketCap":4662460107},{"date":"2025-09-19","current":-23.051901,"twenty":-28.060478,"median":-27.021811,"eighty":-25.478949,"marketCap":4593433106},{"date":"2025-09-26","current":-21.933119,"twenty":-28.003961,"median":-26.881441,"eighty":-23.835003,"marketCap":4359159651},{"date":"2025-10-03","current":-19.179371,"twenty":-27.951558,"median":-26.814509,"eighty":-23.612343,"marketCap":4545323379},{"date":"2025-10-10","current":-18.42629,"twenty":-27.909584,"median":-26.722604,"eighty":-23.450061,"marketCap":4360487033},{"date":"2025-10-17","current":-18.280755,"twenty":-27.87397,"median":-26.671617,"eighty":-23.093007,"marketCap":4322679342},{"date":"2025-10-24","current":-17.856771,"twenty":-27.855424,"median":-26.557884,"eighty":-22.535934,"marketCap":4223959260},{"date":"2025-10-31","current":-16.854881,"twenty":-27.829876,"median":-26.452186,"eighty":-21.933119,"marketCap":3992912259},{"date":"2025-11-07","current":-16.17341,"twenty":-27.822718,"median":-26.363703,"eighty":-19.806882,"marketCap":3829078931},{"date":"2025-11-14","current":-14.606062,"twenty":-27.750423,"median":-26.249352,"eighty":-18.799844,"marketCap":3467805439}],"updateTime":1763362783940},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583635659","title":"每日卖空追踪 | 维升药业-B 11月14日卖空量成交100股，卖空比例为0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583635659","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583635659?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 16:30","pubTimestamp":1763109032,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间11月14日，跌4.18%，卖空量成交100股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114164018a4a11b3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114164018a4a11b3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2583915625","title":"维升药业尾盘涨超4%公司在进博会达成多项合作携两款全球创新药物登场亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2583915625","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583915625?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 15:15","pubTimestamp":1763018100,"startTime":"0","endTime":"0","summary":"港股维升药业-B(02561)尾盘涨超4%，截至发稿涨4.05%，报34.98港元，成交额96.64万港元。11月6日第八届进博会期间，维升药业达成多项合作，与东富龙达成双腔冻干制剂技术战略合作，还与临港新片区管委会等签署产业协同协议，推动“全球创新、中国加速”战略进一步落地。此外，维升药业今年首次以参展商身份亮相进博会，携两款全球创新药物登场，包括全球首个且唯一用于治疗成人慢性甲状旁腺功能减退症（HP）的激素替代治疗药物帕罗培特立帕肽，以及致力于成为“潜在同类最佳”的隆培生长激素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511131526239501affd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511131526239501affd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2582312262","title":"维升药业-B盘中异动 早盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582312262","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582312262?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 10:27","pubTimestamp":1762828061,"startTime":"0","endTime":"0","summary":"2025年11月11日早盘10时27分，维升药业-B股票出现异动，股价急速下挫5.02%。资金方面，该股资金流入18.1122万港元，流出16.5002万港元。维升药业-B股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，旺山旺水-B、嘉和生物-B、华康生物医学涨幅较大，振幅较大的相关个股有旺山旺水-B、嘉和生物-B、维升药业-B，振幅分别为14.47%、12.67%、7.64%。维升药业-B公司简介：维升药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111102741a49898d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111102741a49898d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2582804221","title":"打破“进口依赖”，中国医药企业创新速度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2582804221","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582804221?lang=zh_cn&edition=fundamental","pubTime":"2025-11-11 00:05","pubTimestamp":1762790700,"startTime":"0","endTime":"0","summary":"在这场全球经贸盛会上，中国医药健康产业呈现出前所未有的创新活力：从AI赋能的智慧医疗，到全球新药加速落地，一系列变革正在推动行业从“追赶者”走向“共创者”。在肿瘤治疗领域，复星医药同样带来多项创新突破。同时，复星凯瑞的第二款CAR-T产品也已提交上市申请。以“全球重要采购方”的角色，向世界传递出中国对创新药械的稳定需求和扩大采购的明确意愿。正如复星国际董事长郭广昌所言，中国的医药创新越来越获得全世界的认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111100081394fbb7d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111100081394fbb7d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161","02196"],"gpt_icon":0},{"id":"2581001197","title":"直通进博会 | 进博首秀即双签约！维升药业携手东富龙、临港新片区共筑生物医药生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001197","media":"新华财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001197?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 11:19","pubTimestamp":1762485572,"startTime":"0","endTime":"0","summary":"深耕临港产业生态 夯实本土发展根基值得关注的是，维升药业是临港新片区洋山特殊综合保税区重点引进的一家专注于内分泌相关治疗领域的创新型生物医药企业，治疗范围涵盖成人内分泌、儿童内分泌及内分泌罕见病。此次维升药业与临港新片区管委会、临港集团物贸平台的签约，则进一步深化了公司与临港的产业协同关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110711195997598c36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110711195997598c36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2581001166","title":"维升药业进博首秀：“全球创新、中国加速”战略持续落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001166","media":"环球网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001166?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 09:32","pubTimestamp":1762479128,"startTime":"0","endTime":"0","summary":"11月5日，内分泌领域创新药企维升药业首次以参展商身份亮相第八届中国国际进口博览会，携两款全球创新药物重磅登场——“全球首创”药物帕罗培特立帕肽凭借其卓越创新性入选本届“进博好物”；另一致力于成为“潜在同类最佳”药物隆培生长激素也同步首展，充分彰显维升药业“全球创新、中国加速”的战略实践。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107093448a6e73895&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251107093448a6e73895&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2580479259","title":"维升药业-B(02561.HK)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580479259","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580479259?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 10:33","pubTimestamp":1762137194,"startTime":"0","endTime":"0","summary":"维升药业-B(02561.HK)涨超4%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511033553273518.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511033553273518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2580259870","title":"港股异动 | 维升药业-B(02561)涨超4% 帕罗培特立帕肽近期在博鳌完成首例处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2580259870","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580259870?lang=zh_cn&edition=fundamental","pubTime":"2025-11-03 10:22","pubTimestamp":1762136549,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B涨超4%，截至发稿，涨4.68%，报39.8港元。据悉，该药目前已在欧美主要国家获批上市，是全球首个且唯一一款甲旁减激素替代治疗药物。维升药业首席执行官兼执行董事卢安邦表示，帕罗培特立帕肽在博鳌完成首例处方，是维升药业致力于内分泌领域创新的重要一步。公司将继续与各方紧密合作，加速推动该药国内全面获批，并持续深耕内分泌创新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"628fecc566bce7ba17e7dea241a462ec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575741574","title":"维升药业-B(02561)：陆楹已获委任为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2575741574","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575741574?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 17:54","pubTimestamp":1760349298,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，陆楹已获委任为公司首席财务官，自2025年10月13日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575684402","title":"维升药业-B10月13日主力净流出23.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2575684402","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575684402?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 16:15","pubTimestamp":1760343352,"startTime":"0","endTime":"0","summary":"10月13日, 维升药业-B股价跌1.40%，报收40.94元，成交金额126.9万元，换手率0.03%，振幅3.08%，量比0.98。维升药业-B今日主力资金净流出23.9万元，上一交易日主力净流出0万元。该股近5个交易日下跌5.80%，主力资金累计净流出75.7万元；近20日主力资金累计净流出361.7万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013162107972ad22d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013162107972ad22d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2574135261","title":"维升药业-B10月09日主力净流出51.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2574135261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574135261?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 16:15","pubTimestamp":1759997744,"startTime":"0","endTime":"0","summary":"10月09日, 维升药业-B股价跌2.95%，报收42.70元，成交金额159.7万元，换手率0.03%，振幅3.68%，量比1.16。维升药业-B今日主力资金净流出51.8万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.47%，主力资金累计净流出51.8万元；近20日主力资金累计净流出337.8万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009161951a6b1a6da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009161951a6b1a6da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2573362583","title":"维升药业-B午前涨超3% 隆培促生长素有望年内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2573362583","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573362583?lang=zh_cn&edition=fundamental","pubTime":"2025-10-06 11:42","pubTimestamp":1759722120,"startTime":"0","endTime":"0","summary":"　　维升药业-B午前股价上涨3.08%，现报44.80港元，成交额104.211万港元。　　根据维升药业招股书，公司研发进展最快的是隆培促生长素，公司预计在2025下半年国内获批上市，有望成为国内第三款上市的长效生长激素。今年7月，维升又与安科生物达成合作，共同推进产品的商业化，未来市场前景值得期待。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-10-06/doc-infsxkpt2665338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2572522775","title":"创新药全链条高景气持续，维升药业-B(02561)或迎“戴维斯双击”","url":"https://stock-news.laohu8.com/highlight/detail?id=2572522775","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572522775?lang=zh_cn&edition=fundamental","pubTime":"2025-10-03 08:55","pubTimestamp":1759452900,"startTime":"0","endTime":"0","summary":"在港股创新药“差异化兑现”周期中，市场积极寻求既有“估值修复+产品兑现”双重逻辑，又兼具业绩确定性与长期成长空间的稀缺投资标的，维升药业-B或属其中。据了解，维升药业致力于提供同类首创或同类最优的内分泌疾病产品和治疗方案。站在当前时点，创新药企业估值重构的核心在于“产品兑现能力”，维升药业核心产品即将进入商业化阶段的优势，在当前“盈利驱动”的板块逻辑中尤为突出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161","BK1574","06978","159992"],"gpt_icon":0},{"id":"2569775672","title":"维升药业-B09月23日遭主力抛售21.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569775672","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569775672?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 16:16","pubTimestamp":1758615365,"startTime":"0","endTime":"0","summary":"09月23日, 维升药业-B股价跌1.66%，报收42.70元，成交金额122.7万元，换手率0.03%，振幅2.12%，量比0.87。维升药业-B今日主力资金净流出21.5万元，上一交易日主力净流出57.1万元。该股近5个交易日下跌6.11%，主力资金累计净流出78.6万元；近20日主力资金累计净流入11.5万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923163752a7312fae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923163752a7312fae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2569275790","title":"大摩：市场对生物科技股认可度提升 推动股价跑赢大市 看好康方生物(09926)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2569275790","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569275790?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 09:47","pubTimestamp":1758592020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹发布研报称，在港上市的中国生物科技股总市值由年初至今累升154%，远超恒指同期的34%升幅，相信是反映了市场对本土药企创新能力的认可度发生重大转变，预期美联储加快减息步伐将推动风险偏好调整，推动资金流向中国生物科技等增长型板块。惟大摩预期，个别股分表现仍取决于公司基本面，包括商业化执行力及创新研发进度，看好具短期催化剂的公司，如康方生物(09926)、诺诚健华(09969)、和誉-B(02256)、信达生物(01801)、映恩生物-B(09606)等，另外亦给予维升药业-B(02561)及再鼎医药(09688)“跑赢大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348784397.USD","LU0561508036.HKD","LU2097828714.EUR","09969","BK1161","LU0348766576.USD","LU2476274720.SGD","LU0348735423.USD","02561","LU0417516571.SGD","IE00B5MMRT66.SGD","BK1583","LU0455707207.USD","IE00B543WZ88.USD","HK0000500386.USD","LU2097828631.EUR","IE00BPRC5H50.USD","LU0502904849.HKD","LU2328871848.SGD","01801","02256","159837","LU0348767384.USD","HK0000252152.HKD","BK1589","LU2097828474.EUR","LU0540923850.HKD","LU1794554557.SGD","LU2543165471.USD","LU2097828557.USD","LU0417516902.SGD","LU2476274308.USD","LU2097828805.USD","LU2778985437.USD","LU0348825331.USD","LU1969619763.USD","LU2488822045.USD","LU0417516738.SGD","LU0348783233.USD","09926","LU1720050803.USD","LU0634319403.HKD","09606","BK1574","LU0348827113.USD","LU2242644610.SGD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2569758685","title":"维升药业-B09月22日主力净流出57.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2569758685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569758685?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 16:15","pubTimestamp":1758528922,"startTime":"0","endTime":"0","summary":"09月22日, 维升药业-B股价跌1.14%，报收43.42元，成交金额161.0万元，换手率0.03%，振幅1.87%，量比1.21。维升药业-B今日主力资金净流出57.1万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.94%，主力资金累计净流入33.0万元；近20日主力资金累计净流入33.0万元，其中净流入天数为1日。该股主力净额占比0.01%，港股市场排名2345/2670。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161642a72ee976&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922161642a72ee976&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2567105050","title":"维升药业-B09月16日主力净流入90.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2567105050","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567105050?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 16:16","pubTimestamp":1758010568,"startTime":"0","endTime":"0","summary":"09月16日, 维升药业-B股价涨2.71%，报收45.48元，成交金额327.7万元，换手率0.06%，振幅5.87%，量比5.92。维升药业-B今日主力资金净流入90.1万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.40%，主力资金累计净流入90.1万元；近20日主力资金累计净流入64.0万元，其中净流入天数为1日。该股主力净额占比0.02%，港股市场排名271/2670。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091616241097959d25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091616241097959d25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2567812269","title":"横盘迷雾下的价值火山：维升药业-B（2561.HK）正站在价值重构临界点","url":"https://stock-news.laohu8.com/highlight/detail?id=2567812269","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567812269?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 10:02","pubTimestamp":1757988142,"startTime":"0","endTime":"0","summary":"当一款重磅产品进入商业化倒计时，当全链条战备已搭建完毕，这种僵持注定只是暴风雨前的宁静，维升药业也正面临价值重估的关键节点。","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2840463","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2564866024","title":"长效生长激素“元年”启幕，从“日剂”到“周剂”百亿市场竞争格局生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2564866024","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564866024?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 08:02","pubTimestamp":1756684948,"startTime":"0","endTime":"0","summary":"国内长效生长激素市场正逐渐从单一参与者变为维升药业、特宝生物、金赛药业、安科生物、诺和诺德等多方竞争的格局。弗若斯特沙利文数据显示，预计国内长效生长激素市场规模将在两年内超过短效生长激素，并在2030年占据生长激素全市场73.8%。相比于国内GLP-1长效制剂百条管线激烈角逐的盛况，长效生长激素的竞争相对缓和。据梳理，过往在长效生长激素研发过程中“摔跟头”的企业不在少数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901080521a4abf309&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901080521a4abf309&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2346227817.USD","BK4588","O","BK4599","IE00BMG7P694.USD","02561","BK4532","LU1093756325.SGD","PEG","BK4007","IE00BMG7P926.USD","NVO","IE00BKVL7J92.USD","LU1093756168.USD","IE00BMG7P819.SGD","BK4208","IE00BMG7P587.USD","IE00BD4GTT62.SGD","BK4585","LU0154236417.USD","IE00BZ1G4Q59.USD","IE00BD4GTV84.USD","IE00BD4GTW91.USD"],"gpt_icon":1},{"id":"2562433740","title":"维升药业-B(02561)发布中期业绩 研究及开发成本4662.1万元 同比增加19.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562433740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562433740?lang=zh_cn&edition=fundamental","pubTime":"2025-08-27 22:45","pubTimestamp":1756305931,"startTime":"0","endTime":"0","summary":"于2023年12月，集团与药明生物订立了合作协议，据此，药明生物将作为技术转移的本地CDMO 进行工艺开发和验证，实现生产技术的本地化。截至2025年6月，已完成关键试剂及中间体的技术转移小试研发，集团的目标是在2025年年末或之前完成核心产品原液的技术转移小试研发，全部技术转移及本地化预计将于2027 年完成，届时将赋予集团与药明生物合作生产核心产品药物原液的技术能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1336733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}]}}